AIM ImmunoTech Inc. (AIM) compared with its closest peers (INTS, PASG, INAB, SNTI, CELZ). Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| Intensity Therapeutics, Inc. (INTS) | $15.88M | -0.0 |
| Passage Bio, Inc. (PASG) | $14.09M | -0.8 |
| IN8bio, Inc. (INAB) | $12.52M | -0.5 |
| Senti Biosciences, Inc. (SNTI) | $11.84M | -0.4 |
| Creative Medical Technology Holdings, Inc. (CELZ) | $8.64M | -0.8 |
| VivoSim Labs, Inc. (VIVS) | $4.25M | -0.3 |
| Calidi Biotherapeutics, Inc. (CLDI) | $3.41M | -0.2 |
| Ernexa Therapeutics Inc. (ERNA) | $2.90M | — |
| Nexentis Technologies Inc. (NXTS) | $2.60M | — |
| HCW Biologics Inc. (HCWB) | $2.45M | — |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
AIM overview · AIM earnings · AIM financials · AIM KPIs · AIM investor relations · AIM ownership · AIM filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.